Emcure Pharmaceuticals Limited (EMCURE) Share Analysis
NSE · Healthcare · Healthcare
Emcure Pharmaceuticals Limited (NSE: EMCURE) is an Indian listed company in the Healthcare sector and a constituent of NIFTY 500, NIFTY MidSmallcap 400, NIFTY Smallcap 250. As of 14 Nov 2026, the share price was ₹2,362.00, P/E 40.3, ROE 20.1%.
Get the AI verdict on EMCURE: BUY, BUY ON DIPS, WAIT or EXIT
Sign in for the full analysis — AI fundamental and technical analysis, recent news, and one verdict with an entry zone, two targets and a stop-loss, for a 3-month, 1-year, 3-year or 5-year horizon. A free plan is available.
EMCURE chart with trendlines
Is EMCURE a buy right now?
Sign in free for the AI verdict with entry zone, targets and stop-loss.
About Emcure Pharmaceuticals Limited
Stored fundamentals as of 14 Nov 2026 — not a live quote. Signed-in analysis uses same-day data.
EMCURE key facts
| Price and valuation | |
|---|---|
| Share price | ₹2,362.00 |
| Market cap | ₹44,804 Cr |
| P/E ratio | 40.3 |
| P/B ratio | 8.38 |
| EPS | ₹57.66 |
| Book value per share | ₹282.00 |
| Dividend yield | 0.15% |
| 52-week range | |
| 52-week high | ₹2,429.90 |
| 52-week low | ₹1,312.30 |
| Face value | ₹10.00 |
| Shareholding pattern | |
| Promoters | 77.82% |
| FIIs | 4.94% |
| DIIs | 8.49% |
| Public | 8.75% |
Index membership: NIFTY 500, NIFTY MidSmallcap 400, NIFTY Smallcap 250.
Learn to read these numbers
- Metrics glossary — what P/E, ROE, ROCE and debt-to-equity mean.
- Investment Blogs — free lessons on fundamental and technical analysis.
- AI stock picks and Discover stocks by sector and index.
- How Stock-Analyze works — what the AI analysis and verdict cover.